Author, as appears in the article.: Aragonès G; Alonso-Villaverde C; Pardo-Reche P; Rull A; Beltrán-Debón R; Rodríguez-Gallego E; Fernández-Sender L; Camps J; Joven J

Department: Medicina i Cirurgia Bioquímica i Biotecnologia

URV's Author/s: Aragonès Bargalló, Gerard / Beltrán Debón, Raúl Alejandro / Camps Andreu, Jorge / Joven Maried, Jorge / Rodríguez Gallego, Esther / RULL AIXA, ANNA

Keywords: Triglyceride-rich lipoproteins Therapy Necrosis-factor-alpha Lipid disorders Glucose-metabolism Genetic polymorphisms Density-lipoprotein cholesterol Arterial inflammation Apolipoprotein-b metabolism A-i

Abstract: Background: The recently observed association between the APOC3-related rs10892151 polymorphism and serum triglyceride levels has prompted us the possibility to explore whether this genetic variant may play a major role in human immunodeficiency virus (HIV)/antiretroviral therapy-induced dyslipidemia.Methods: We determined the rs10892151 genotype distribution and serum apolipoprotein (apo) C-III concentration in a group of HIV-infected patients (n = 208) and in a group of age and sex-matched healthy volunteers (n = 200). Circulating lipid and lipoprotein levels were followed for 12 months after antiretroviral treatment initiation in the HIV-infected group.Results: There were no significant variations in the frequency of the A allele between the healthy and HIV-infected groups (7.5 vs. 8.6%, respectively; p = 0.7); additionally, the A allele was not related to serum apo C-III concentration. However, among patients receiving protease inhibitor (PI) treatment, carriers of the A allele had significantly increased serum triglyceride (5.76 ± 2.54 mmol/L) and total cholesterol (6.63 ± 2.85 mmol/L) concentrations together with depressed levels of HDL-cholesterol (0.75 ± 0.3 mmol/L) when compared with patients not carrying the allele (2.43 ± 1.32, 5.2 ± 2.17 and 1.24 ± 0.4 mmol/L, respectively) at the end of the study. This effect was only evident for HDL-cholesterol concentration when patients were treated with non-nucleoside reverse transcriptase inhibitors (1.05 ± 0.4 vs. 1.28 ± 0.4 mmol/L).Conclusions: The A allelic variant of the rs10892151 polymorphism is not associated with serum apo C-III concentration, but predisposes HIV-infected patients to less favorable lipid profile, particularly in those patients treated with PIs. © 2011 Aragonès et al; licensee BioMed Central Ltd.

Thematic Areas: Saúde coletiva Química Odontología Nutrição Medicina iii Medicina ii Medicina i Matemática / probabilidade e estatística Interdisciplinar Genetics (clinical) Genetics & heredity Genetics Farmacia Engenharias iv Engenharias iii Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade

licence for use: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 14712350

Author's mail: jorge.camps@urv.cat gerard.aragones@urv.cat raul.beltran@urv.cat esther.rodriguez@urv.cat jorge.joven@urv.cat

Author identifier: 0000-0002-3165-3640 0000-0001-9691-1906 0000-0003-2749-4541

Record's date: 2023-02-19

Papper version: info:eu-repo/semantics/publishedVersion

Link to the original source: https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-12-120

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Bmc Medical Genetics. 12 120-

APA: Aragonès G; Alonso-Villaverde C; Pardo-Reche P; Rull A; Beltrán-Debón R; Rodríguez-Gallego E; Fernández-Sender L; Camps J; Joven J (2011). Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. Bmc Medical Genetics, 12(), 120-. DOI: 10.1186/1471-2350-12-120

Article's DOI: 10.1186/1471-2350-12-120

Entity: Universitat Rovira i Virgili

Journal publication year: 2011

Publication Type: Journal Publications